Abstract: Provided is a resin-linear organopolysiloxane block copolymer which has a high degree of freedom in formulation due to excellent compatibility with other materials, in addition to exhibiting excellent film forming properties and followability of a film, while the stickiness of a film is suppressed. The resin-linear organopolysiloxane block copolymer has: a resin structure (A1) block that has siloxane units represented by R1SiO3/2 (wherein R1 represents a monovalent organic group, a hydroxyl group, or an alkoxy group having 1 to 6 carbon atoms) and SiO4/2; and a linear structure (A2) block represented by (R2SiO2/2)n (wherein n represents a number of 5 or more while R represents an alkyl group, a fluoroalkyl group, or an aryl group) in each molecule. The resin structure (A1) and the linear structure (A2) are linked to each other by an Si—O—Si bond, and an Si atom bonded to the resin structure (A1) constitutes an RSiO3/2 unit.
Type:
Application
Filed:
October 3, 2017
Publication date:
August 13, 2020
Inventors:
Haruhiko FURUKAWA, John Bernard HORSTMAN, Tomohiro IIMURA, Tadashi OKAWA, Steven SWIER
Abstract: Methods and compositions for preventing or reducing hair frizz. The compositions are preferably oil-in-water or water-in-oil emulsions comprise at least one polysiloxane fluid component selected from an amodimethicone and a polysiloxane component comprising a plurality of hindered amine side chains. The compositions also comprise a silicone-compatible, volatile or non-volatile liquid carrier component, preferably comprising a component selected from a low molecular weight, volatile siloxy component; a hydrocarbon; and an alcohol. The compositions are preferably combing cremes, sprays or mousses, and are suitable for use a “leave-in” hair care product, or as a touch-up hair care product suitable for use during the day.
Abstract: The invention relates to a fruit flavoring that produces a yellow taste sensation and that is obtained by (a) contacting and/or mixing at least one fruit flavoring producing a red taste sensation with (b) at least one fruit flavoring producing a green taste sensation.
Abstract: One aspect of the present disclosure relates to a cosmetic composition including a citron oil bead. More specifically, the cosmetic composition includes an appropriate amount of a citron oil bead including a citron oil, a behenyl alcohol, a jojoba ester, and a hydrogenated C6-14 polyolefin in an appropriate weight ratio. The cosmetic composition improves the preference for the fragrance and stabilize the mind and body with the fragrance to induce a comfortable sleeping, thereby improving the quality of sleep.
Type:
Application
Filed:
February 7, 2020
Publication date:
August 13, 2020
Applicant:
AMOREPACIFIC CORPORATION
Inventors:
Byeongbae JEON, Yewon KIM, Jisue PARK, Gusang KWON
Abstract: A method for preparing Ganoderma lucidum extract using an eco-friendly extraction technique is disclosed. A Ganoderma lucidum extract prepared thereby and a cosmetic composition containing the extract, and their uses are disclosed. The extraction technique use an aqueous cyclodextrin solution alone or in combination with ultrasonic extraction to afford a Ganoderma lucidum extract containing a high concentration of the effective ingredient triterpenoid.
Type:
Application
Filed:
September 20, 2018
Publication date:
August 13, 2020
Applicant:
AMOREPACIFIC CORPORATION
Inventors:
Jin Sup SHIM, Eun Jung LEE, Nok Hyun PARK, So Woong CHOI, Yong Jin KIM
Abstract: Disclosed is a topical composition comprising: (i) a first extract comprising botanical actives extracted from Emblica officinalis; and, (ii) a second extract comprising volatile botanical actives extracted from Camellia sinensis, wherein said second extract comprises E-2-hexenal and linalool at ratio of 0.1:1 to 10:1 parts by weight. Also disclosed is a method of activation of Nrf2, a method of upregulating gene expression of H01 in melanocytes and a method of upregulating gene expression of NQ01 in fibroblasts comprising a step of applying a topical cosmetic composition of the first aspect.
Type:
Application
Filed:
July 16, 2018
Publication date:
August 13, 2020
Applicant:
Conopco, Inc., d/b/a UNILEVER
Inventors:
Paul Mark DIAS, Vijay Ramchandra GADGIL, Nidhi JAGADISH
Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.
Type:
Application
Filed:
March 5, 2020
Publication date:
August 13, 2020
Applicant:
KASHIV BIOSCIENCES, LLC
Inventors:
Siva Ram Kiran Vaka, Paras Jariwala, Jaydeep Vaghashiya, Atsawin Thongsukmak, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
Abstract: The present application relates to methods to administer to a patient a thermally neutral inhalation gas composition that includes oxygen and a mixture of inert gases. The mixture of inert gases includes a first compound such as xenon, and a second compound having hypothermal properties, such as helium. In the methods, a thermally neutral inhalation gas composition including oxygen and a mixture of inert gases is selected and the thermally neutral inhalation gas composition is administered to the patient at an inhalation temperature of a specified range such that the body temperature of the patient is maintained at a specified temperature.
Abstract: A method for injecting aqueous buffered acid solutions and alkaline solutions into the hypodermis for partial thickness hypodermal burns or to cause denaturation of cells below the dermis.
Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.
Type:
Application
Filed:
September 3, 2019
Publication date:
August 13, 2020
Applicant:
The Board of Regents of the University of Texas System
Inventors:
Christopher C. CAPELLI, Phillip C. PHAN, Allen W. BURTON
Abstract: The present disclosure relates to improved supraparticles loaded with high levels of payload and methods for their production. Such supraparticles may be used in a range of therapeutic applications, for example, to improve growth or survival of cells and/or treat disease.
Type:
Application
Filed:
September 20, 2018
Publication date:
August 13, 2020
Inventors:
Andrew Wise, Frank Caruso, Mattias Bjornmalm, Yutian Ma
Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.
Type:
Application
Filed:
May 1, 2020
Publication date:
August 13, 2020
Inventors:
Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
Abstract: According to some aspects, this application provides devices and methods for treating cystinosis in a patient. Removable intra-ocular devices and contact lenses containing cystine-sequestering materials effective for uptake of cystine from the eyes of a patient having cystinosis are provided. Methods of making the cystine-sequestering contact lenses are also provided.
Abstract: A cell autophagy inhibitor using a rubiaceae-type cyclopeptide as the active ingredient, and is particularly used for inhibiting KRAS mutation, especially protective autophagy of KRAS dependent tumor cells, and promoting tumor cell apoptosis; the inhibitor is preferably a nano-micelle injection, which can be used to the preparation of a medicament for treating and preventing KRAS-related cancers including colon cancer, rectal cancer, lung cancer and pancreatic cancer. The cell autophagy inhibitor of the present invention can effectively inhibit the protective autophagy of tumor cells, and its active ingredient rubiaceae-type cyclopeptides have a wide range of sources, mature extraction processes, diversified dosage forms and administration methods, and can be used to the treatment and prevention of KRAS-related cancers and have broad clinical application prospects.
Abstract: Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent; and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.
Abstract: Present invention relates to a formulation from natural product. The formulation is LDV liposomal formulation of Photo System-I (PSI) which causes apoptotic death of cancer cells through ROS generation and a simple way for targeted delivery of the said formulation specifically to melanoma cancer cell. LDV liposomal formulation of PSI was prepared for targeted delivery to melanoma cancer cell. Through this targeted delivery inventors have shown that LDV liposomal formulation of PSI specifically kills melanoma cancer cells leaving normal cells unaffected. The present invention elucidates that LDV liposomal formulation of PSI is more potent anti-cancer agent than doxorubicin for melanoma.
Abstract: The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks.
Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.
Type:
Application
Filed:
December 17, 2019
Publication date:
August 13, 2020
Inventors:
Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
Abstract: Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.
Type:
Application
Filed:
February 7, 2020
Publication date:
August 13, 2020
Inventors:
Andrea PFEIFER, Andreas MUHS, Maria PIHLGREN BOSCH, Marija VUKICEVIC VERHILLE, Nicolas PIOT, Saroj Raj GHIMIRE, Elizabeth Anne RAMSBURG, Donata DE MARCO, Charlotte SADAKA
Abstract: A wound sealing powder, method of making a wound sealing powder, and method of using a wound sealing powder to reduce blood flow from a wound are provided. Specifically, the wound sealing powder utilizes a particulate powder material of an effective amount of an insoluble cation exchange material wherein the majority of the particles in the powder have particle sizes of less than approximately 48 microns.
Abstract: The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and/or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.
Type:
Application
Filed:
July 25, 2018
Publication date:
August 13, 2020
Inventors:
Chase Spenser Coffman, Lyndon Fitzgerald Charles, Jr., Paul Brown, Daniel Benjamin Dadon, Lisa Liu, Cory Robinson, Dale Arlington Thomas, III
Abstract: Embodiments described herein generally relate to methods of homogeneous wetting of biopolymers, derivatives therefrom and synthetic polymers, and, their applications.
Type:
Application
Filed:
October 9, 2018
Publication date:
August 13, 2020
Inventors:
Richard Dolph ANDERSEN, Annette ASSOGBA-ZANDT, Elena MALTSEVA, Andreas VOIGT
Abstract: This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90 ranging from 35 ?m to 90 ?m as measured by laser light diffraction and wherein the tablet has a gemcabene dissolution profile characterized by a % dissolution profile of at least 80% in pH 5.0 potassium acetate buffer at 37° C.±0.5° C. in no more than 45 minutes as measured by ultra-violet/visible light absorption using a detection wavelength range of 216 nm to 230 nm. This invention further provides gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6. The tablets and gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6 are useful for treating or preventing liver disease or an abnormal liver condition, a disorder of lipoprotein or glucose metabolism, a cardiovascular or related vascular disorder, a disease caused by fibrosis (such as liver fibrosis), or a disease associated with inflammation (such as liver inflammation).
Type:
Application
Filed:
October 17, 2019
Publication date:
August 13, 2020
Inventors:
Daniela Carmen ONICIU, Charles Larry BISGAIER, Matthew Benjamin GREENE
Abstract: The present disclosure relates to bilayer tablets comprising a second layer comprising a ?-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.
Type:
Application
Filed:
December 23, 2019
Publication date:
August 13, 2020
Inventors:
Michael DUNNE, Tom LOUGHMAN, Aaron CAMERON
Abstract: This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Type:
Application
Filed:
January 17, 2020
Publication date:
August 13, 2020
Inventors:
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
Type:
Application
Filed:
March 23, 2020
Publication date:
August 13, 2020
Applicant:
Acorda Therapeutics, Inc.
Inventors:
Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism.
Type:
Application
Filed:
May 1, 2020
Publication date:
August 13, 2020
Applicant:
Impax Laboratories, LLC
Inventors:
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.
Abstract: This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen activator receptor (uPAR) insulin-like growth factor 1 receptor (IGF1R), EGFR, HER2, and/or other member of the ErbB family of receptors. In certain embodiments, the molecule that binds a cancer marker is an amino terminal fragment of uPA or variant capable of binding uPAR and/or IGF1 or variant capable of binding IGF1R. In certain embodiments, the toxic polypeptide is a bacterial exotoxin.
Abstract: The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.
Type:
Application
Filed:
April 30, 2020
Publication date:
August 13, 2020
Inventors:
WILLEM MULDER, JORDI OCHANDO, ZAHI FAYAD, MIHAI NETEA, LEO JOOSTEN
Abstract: Provided herein are stable, dissolvable films containing active ingredients, such as antimicrobial composition, antiviral compositions, or anti-retroviral compositions for intravaginal or intrarectal placement to provide prophylaxis against viral infections.
Abstract: The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.
Type:
Application
Filed:
April 27, 2020
Publication date:
August 13, 2020
Applicant:
Mylan Inc.
Inventors:
Russell Adam Baird, Brad L. Barnett, Russell D. Beste
Abstract: A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.
Type:
Application
Filed:
April 29, 2020
Publication date:
August 13, 2020
Inventors:
Adam S. Cantor, Terrance W. Ocheltree, Cynthia A. Robles
Abstract: The present invention provides a method for treating a subject having a clinical condition associated with increased level of L1 expression. The method generally includes determining the expression level of L1 in a subject and administering a TGF-?1 inhibitor to a subject having an increased level of L1 expression. The clinical conditions that can be treated using the method of the invention include, but are not limited to, cancer, chronic obstructive pulmonary disease (COPD), atherosclerosis and pulmonary vascular disease as well as other fibrotic and inflammatory diseases.
Type:
Application
Filed:
March 28, 2017
Publication date:
August 13, 2020
Inventors:
Kenneth RAMOS, Elsa M. REYES-REYES, Pasano BOJANG, Patrick Silva
Abstract: The invention pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.
Type:
Application
Filed:
October 4, 2018
Publication date:
August 13, 2020
Applicants:
SORBONNE UNIVERSITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS, KYOTO UNIVERSITY
Inventors:
Dominique Gauguier, Fumihiko Matsuda, François Brial
Abstract: A method of treating, suppressing, or reducing the severity of hyperproliferative disease, includes the administration of a therapeutically effective amount of a composition having safranal to a subject with a hyperproliferative disease in which Cdc25B is over-expressed. The hyperproliferative disease may be a benign tumor or a malignant tumor. The therapeutically effective amount may be administered orally or parenterally. In representative embodiments, the amount of safranal may be from about 10 mg/day to about 1000 mg/day per kg body weight of the subject.
Abstract: Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods involve administering a therapeutically effective amount of a composition including safranal or its pharmaceutically acceptable pro-drug, and a pharmaceutically acceptable carrier to the subject. The disclosed methods may be used to treat, suppress, or reduce the severity of various liver cancers, including hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, a metastatic liver cancer, and combinations thereof.
Abstract: An anticancer agent for cancers in which an abundance of cyclin D1 protein is greater than that in a control, the anticancer agent including a compound represented by the following Formula (1) as an active ingredient (in Formula (1), R1 to R11 each independently represent a hydrogen atom, an aliphatic group having 1 to 30 carbon atoms, or a group represented by Formula RCO— (where, R represents an aliphatic group having 1 to 30 carbon atoms, or an aromatic group or heteroaromatic group having 1 to 10 carbon atoms)).
Abstract: A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including Alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.
Type:
Application
Filed:
December 20, 2019
Publication date:
August 13, 2020
Inventors:
Kathleen E. CLARENCE-SMITH, Thomas N. CHASE
Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
Type:
Application
Filed:
April 9, 2020
Publication date:
August 13, 2020
Inventors:
Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
Abstract: A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.
Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.
Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
Type:
Application
Filed:
April 24, 2020
Publication date:
August 13, 2020
Inventors:
Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
Abstract: The subject invention provides materials and methods for preventing, inhibiting or reducing biofilm formation and biofilm infections in subjects. The materials and methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.
Type:
Application
Filed:
October 26, 2017
Publication date:
August 13, 2020
Inventors:
Carolyn L. TWOMEY, Gareth CLARKE, Samuel ZAIDSPINER
Abstract: Methods of increasing perfusion and vascularity in irradiated tissue and of increasing retention of fat cells in a fat graft in irradiated tissue by applying an effective amount of DFO to the irradiated tissue at a treatment site. The DFO may be administered transdermally by applying a transdermal delivery device to a tissue surface at the treatment site in multiple discrete doses. The transdermal delivery system comprises DFO encapsulated in reverse micelles.
Type:
Application
Filed:
September 12, 2018
Publication date:
August 13, 2020
Applicant:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Derrick C. WAN, Geoffrey C. GURTNER, Michael T. LONGAKER
Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.
Type:
Application
Filed:
October 17, 2019
Publication date:
August 13, 2020
Inventors:
Thomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
Abstract: The present invention relates to synthetic capsaicin analogues, tautomers or salts thereof and their use as bioenhancers. The invention provides substituted capsaicyns for use as a bioenhancer, use as a bioenhancer on active substances, in compositions preferably for oral administration, such as in feed, food, pharmaceutical compositions or supplements.
Abstract: Methods of reducing neuronal sensitivity, thereby reducing inflammation and chronic pain, in subjects having diabetes are disclosed herein. Particularly disclosed are methods of administrating the apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE 1/Ref-1) inhibitor, APX3330, to enhance the DNA base excision repair (BER) pathway, thereby reducing neuronal sensitivity to inflammatory mediators and alleviating inflammatory or chronic pain.